Global Neurology Academy

Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
NeuroFrontiers
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
- Shelina Ramnarine, PhD
- Michelle Scargle, MD
- Margaret Emerson, DNP, APRN, PMHNP-BC
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
Global Neurology Academy
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
- Brian P. McDonough, MD, FAAFP
- Ahmed Makhlouf, MD
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiers
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
- Sharon Sha, MD, MS
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiers
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
- Hamid Abuwarda, PhD, BS
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
NeuroFrontiers
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
- Shelina Ramnarine, PhD
- Apurva Bhatt, MD
- Shannon Pagdon, BA
Harnessing AI to Predict and Prevent Schizophrenia Relapse
Harnessing AI to Predict and Prevent Schizophrenia Relapse
NeuroFrontiers
Harnessing AI to Predict and Prevent Schizophrenia Relapse
- Matcheri S. Keshavan, MD
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Clinician's Roundtable
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
- Charles Turck, PharmD, BCPS, BCCCP
- Philip Yeske, PhD
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiers
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
- Sheetal Shroff, MD

Medical News

Medical News
The Impact of Concussion History on Long-Term Health in Former NFL Players
12/08/2025
Read more
Medical News
Unveiling the Role of Choline in Anxiety Disorders: A New Frontier in Mental Health
12/08/2025
Read more
Medical News
FDA Approval of Tonmya: A New Era for Fibromyalgia Treatment
12/08/2025
Read more
Medical News
Evaluating Real-World Applicability of Alzheimer’s Biomarkers in Clinical Settings
12/08/2025
Read more

See more news

CME/CE

Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
CME/CE
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
0.25 credits
- Christyn Edmundson, MD
- Neelam Goyal, MD
0.25 credits
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CE
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
1.00 credit
- Stephen Chrzanowski, MD, PhD
- Aravindhan Veerapandiyan, MD
1.00 credit
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CE
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
0.25 credits
- Christoph U. Correll, MD
- Jonathan M. Meyer
0.25 credits
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits

Clinical Practice

Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
NeuroFrontiers
Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
- Charles Turck, PharmD, BCPS, BCCCP
- Ragy R. Girgis, MD, MS
- Desiree Matthews, PMHNP-BC
Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access
Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access
NeuroFrontiers
Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access
- Charles Turck, PharmD, BCPS, BCCCP
- David Kimhy, PhD
Individualizing gMG Treatment: Defining Success With Each Patient
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
- Omar Sinno, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiers
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
- Michael Weiss, MD

Programs

Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
- Alexandria May, PharmD, BCPS
- Angela Waanders, MD, MPH, MS
- Ashley S. Margol, MD, MS
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Clinician's Roundtable
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Caterina Garone, MD, PhD
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiers
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Global Neurology Academy
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
- Tirisham V. Gyang, MD
- Gates B. Colbert, MD